Healthcare private equity activity strengthened midyear as investors cautiously reentered the market, with deal momentum improving in the second quarter. Biopharma and Asia-Pacific transactions showed the strongest gains, while carveouts and public-to-private deals led overall activity. Asia-Pacific accounted for roughly one-third of global healthcare buyout value, signaling rising regional interest alongside renewed activity in North America, especially for larger deals over $250 million. Although volumes remain below peak levels, improving conditions suggest growing confidence as investors test the waters and selectively pursue opportunities across structures, regions, and subsectors.

Join for free to read